touchMDT Investigating immunotherapies for endometrial cancer: Working as a MDT to identify patients and improve outcomes
Select a discussion in the hub to watch our multidisciplinary faculty share their expert perspectives on the potential of immunotherapies to improve the management of patients with endometrial cancer.Overview & Learning Objectives
A MDT discusses a 62-year-old female with recurrent, advanced-stage EC.
What clinical factors guide treatment?
Gynaecological Oncologist & Medical Oncologist
A gynaecological oncologist and a medical oncologist discuss the latest data on PD-1/PD-L1 inhibitors and what they mean for patients with EC.
A gynaecological oncologist and a medical oncologist review the latest immunotherapy data in EC.Learn more Back to MDT Hub
Gynaecological Oncologist, Medical Oncologist & Pathologist
A gynaecological oncologist, a medical oncologist and a pathologist, as a multidisciplinary tumour board, review a patient profile and describe how they would determine suitability for PD-1/PD-L1 inhibitor therapy.
The MDT tumour board discusses a patient with EC and key considerations that guide treatment.Learn more Back to MDT Hub
Gynaecological Oncologist & Pathologist
A gynaecological oncologist and a pathologist discuss how patients with EC should be tested to determine suitability for PD-1/PD-L1 inhibitor therapy.
A gynaecological oncologist and a pathologist discuss recommendations for biomarker testing.Learn more Back to MDT Hub